Cardiology Search
Cardiology Cardiology
rheumatic%20fever%20-%20acute
RHEUMATIC FEVER - ACUTE
Acute rheumatic fever is an autoimmune response to a previous group A beta-hemolytic streptococcal (GAS) infection causing acute generalized anti-inflammatory response primarily affecting the heart.
It often presents in patients 5-14 years of age and uncommon before 3 years and after 21 years of age.
Patients presenting with acute rheumatic fever are severely unwell, in extreme pain and requires hospitalization.
Drug Information

Indication: Relief of mild to moderate pain & fever.

Indication: Short-term treatment of upper & lower resp tract, skin & soft tissue, GUT infections. Tab & inj Sh...

Indication: Infections of nose-pharynx tract (tonsillitis, pharyngitis) & of paranasal sinuses; lower resp tract: bron...

Indication: Oral: Lower resp tract infections including bronchitis & pneumonia; skin & soft tissue infections; acu...

Indication: HTN. Adjunct to digitalis &/or diuretic therapy in CHF.

Actimol Menstrual
pamabrom + paracetamol

Indication: Symptomatic relief of bloating, water-wt gain, backache, muscular aches, pre-menstrual & menstrual discomf...

Alka-Seltzer
aspirin + citric acid + sodium bicarbonate

Indication: Relief of headache & upset stomach. Fever, colds & flu discomfort, muscular aches & pains.

Indication: Infections due to gm -ve & +ve organisms & non-penicillinase-producing staph.

Indication: Mild to moderate pain & fever.

Indication: Resp tract, ENT, O&G, skin & soft tissue, bone & dental infections, UTI. Prophylaxis of recurrent ...

1  /  18
1  /  18
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Adding an old gout drug to standard therapy cost-effective post-MI
Elvira Manzano, 13 Apr 2020
A gout drug that’s been around for years reduced the risk of ischaemic cardiovascular (CV) events when given at a low dose in patients who had myocardial infarction (MI) and was cost-effective, an analysis of the COLCOT* trial has shown.
Hyponatraemia in acute HF: Tolvaptan effective, but does not reduce mortality
Christina Lau, 02 Jan 2020

Tolvaptan improves dyspnoea, increases sodium levels and reduces body weight in patients with acute heart failure (HF) with or without hyponatraemia, but no significant effect is seen in mortality or rehospitalization, according to a recent meta-analysis.
TAVR for low-risk patients with bicuspid valves?
Pearl Toh, 15 Apr 2020
Transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic stenosis who are at low surgical risk appears to be safe with low rates of death or disabling stroke at 30 days, according to a study presented at the ACC.20/WCC Virtual Meeting.